SLS is trading at $16.41 (6.22% up) as it extends a sharp late-June rally fueled by oncology pipeline optimism and persistent buyout chatter.
- The stock has surged 58% over the last five sessions, driven by speculative biotech momentum ahead of the REGAL trial readout.
- Recent coverage highlights a significant climb from approximately $9.00 to $12.07, reflecting investor anticipation regarding the upcoming trial verdict.
- Market interest remains high as acquisition speculation continues to circulate alongside the company's clinical developments.